NCT01686334View on ClinicalTrials.gov

Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

DC vaccine

Autologous WT1 mRNA-electroporated DCs

Trial Locations (8)

1090

University Hospital Brussels, Brussels

1200

Cliniques Universitaires Saint-Luc, Brussels

2030

ZNA Cadix, Antwerp

2650

Antwerp University Hospital, Antwerp

4000

Centre Hospitalier Universitaire de Liège, Liège

5530

CHU Mont Godinne, Yvoir

8800

AZ Delta, Roeselare

9000

Ghent University Hospital, Ghent

All Listed Sponsors
collaborator

Kom Op Tegen Kanker

OTHER

collaborator

Stichting tegen Kanker

OTHER

collaborator

Research Foundation Flanders

OTHER

lead

Zwi Berneman

OTHER

NCT01686334 - Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission | Biotech Hunter | Biotech Hunter